GenSight Biologics: Advances in Manufacturing Partnership with Catalent

GenSight Biologics, a biopharmaceutical company focused on retinal neurodegenerative diseases, has successfully transferred the upstream manufacturing phase of LUMEVOQ® to Catalent. This genetic treatment targets Leber hereditary optic neuropathy, a rare disease. This transfer follows the successful production of a batch for the compassionate access program in France. The partnership with Catalent, a specialist in contract development and manufacturing, is expected to improve the yields and analytical methods required for clinical and regulatory trials. GenSight is thus finalizing its marketing authorization strategy and preparing for an international clinical trial for 2026.